P2RX7 and neoplasm: AZ10606120, N-[2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-2-tricyclo[3.3.1.13,7]decylacetamide dihydrochloride (AZ10606120) and 3-[[5-(2,3-Dichlorophenyl)-1H-tetrazol-1-yl]methyl] pyridine hydrochloride (A438079) are P2X7 receptor antagonists, selected for further development because of their improved selectivity for P2X7R, their potential to block P2X7R-dependent inflammasome activities [14, 15, 19], and their demonstrated anti-tumor activities (>50%) in preclinical models [28].